checkAd

     117  0 Kommentare Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries - Seite 3

    Company Contact
    Snehal Patel
    Investor Relations
    Office: (832) 819-3232
    Email: info@greenwichlifesciences.com

    Lesen Sie auch

    Investor & Public Relations Contact for Greenwich LifeSciences
    Dave Gentry
    RedChip Companies Inc.
    Office: 1-800-RED CHIP (733 2447)
    Email: dave@redchip.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries - Seite 3 STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) - Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an …